HPLC-DAD-CAD-based approach for the simultaneous analysis of hydrophobic drugs and lipid compounds in liposomes and for cyclodextrin/drug inclusion complexes

被引:9
作者
Langer, Carolin [1 ]
Suess, Regine [1 ]
机构
[1] Univ Freiburg, Dept Pharmaceut Technol & Biopharm, Inst Pharmaceut Sci, Sonnenstr 5, D-79104 Freiburg, Germany
关键词
HPLC-DAD-CAD method; Liposomes; Cyclodextrin; drug inclusion complexes; Phospholipid quantification; Mitotane; everolimus quantification; Charged aerosol detector (CAD); AEROSOL; EVEROLIMUS; CARCINOMA;
D O I
10.1016/j.jpba.2021.114120
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
In recent decades liposomes have become attractive carriers for hydrophobic drugs to enhance their solubility and improve their therapeutic application. For liposomal drug products, both drug and lipid quantification are required by regulatory authorities, making the implementation of precise quantification methods a step of crucial importance in formulation development and quality control. Therefore, the present study is focused on the development and validation of a simple and time-saving method for the simultaneous analysis of hydrophobic drugs and conventional liposomal components. The new HPLC method was established with a combined detection by a diode array detector (DAD) and a corona charged aerosol detector (CAD). As a wide calibration range of the liposomal components can be achieved (10 & minus;1000 & micro;g/mL), the analysis of samples with different drug to lipid ratios is enabled. Moreover, an excellent precision including repeatability and low limits of detection (< 1.8 & micro;g/mL) and limits of quantification (< 5.9 & micro;g/mL) were accomplished for all analytes. The method was successfully applied to liposomes incorporating mitotane. Everolimus was additionally analyzed as hydrophobic model drug. Furthermore, cyclodextrin/mitotane inclusion complexes were investigated to proof a broad range of applications for the developed method. (c) 2021 Elsevier B.V. All rights reserved.
引用
收藏
页数:7
相关论文
共 28 条
  • [1] Alfonsi R., 2013, Annales Pharmaceutiques Francaises, V71, P186, DOI 10.1016/j.pharma.2013.02.001
  • [2] [Anonymous], 2005, ICH GUID Q2 R1 VAL A, DOI [10.1163/ej.9789004163300.i-1081.897, DOI 10.1163/EJ.9789004163300.I-1081.897]
  • [3] BARTLETT GR, 1959, J BIOL CHEM, V234, P466
  • [4] Charged aerosol detector HPLC as a characterization and quantification application of biopharmaceutically relevant polysialic acid from E. coli K1
    Bossmann, Daniel
    Bartling, Bastian
    de Vries, Ingo
    Winkler, Jonas
    Neumann, Harald
    Lammers, Frank
    Beutel, Sascha
    Scheper, Thomas
    [J]. JOURNAL OF CHROMATOGRAPHY A, 2019, 1599 : 85 - 94
  • [5] Cyclodextrins as pharmaccutical solubilizers
    Brewster, Marcus E.
    Loftsson, Thorsteinn
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (07) : 645 - 666
  • [6] Preparation of asymmetric phospholipid vesicles for use as cell membrane models
    Doktorova, Milka
    Heberle, Frederick A.
    Eicher, Barbara
    Standaert, Robert F.
    Katsaras, John
    London, Erwin
    Pabst, Georg
    Marquardt, Drew
    [J]. NATURE PROTOCOLS, 2018, 13 (09) : 2086 - 2101
  • [7] Adrenocortical carcinoma: a clinician's update
    Fassnacht, Martin
    Libe, Rossella
    Kroiss, Matthias
    Allolio, Bruno
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2011, 7 (06) : 323 - 335
  • [8] Pharmacokinetics of pegylated liposomal doxorubicin - Review of animal and human studies
    Gabizon, A
    Shmeeda, H
    Barenholz, Y
    [J]. CLINICAL PHARMACOKINETICS, 2003, 42 (05) : 419 - 436
  • [9] Gamache PH, 2005, LC GC N AM, V23, P150
  • [10] Efficacy and safety of everolimus treatment on liver transplant recipients: A meta-analysis
    Guan, Tong-Wei
    Lin, Yi-Jin
    Ou, Meng-Ying
    Chen, Ke-Bao
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2019, 49 (12)